Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBT (2016 - 2026)

Usana Health Sciences has reported EBT over the past 17 years, most recently at $15.5 million for Q2 2026.

  • Quarterly EBT fell 7.61% to $15.5 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $40.3 million through Apr 2026, down 38.99% year-over-year, with the annual reading at $41.5 million for FY2026, 45.61% down from the prior year.
  • EBT was $15.5 million for Q2 2026 at Usana Health Sciences, up from $4.2 million in the prior quarter.
  • Over five years, EBT peaked at $47.2 million in Q1 2022 and troughed at $1.8 million in Q3 2025.
  • The 5-year median for EBT is $21.7 million (2022), against an average of $21.8 million.
  • Year-over-year, EBT rose 16.7% in 2023 and then tumbled 90.36% in 2025.
  • A 5-year view of EBT shows it stood at $22.8 million in 2022, then grew by 16.7% to $26.6 million in 2023, then crashed by 60.81% to $10.4 million in 2024, then crashed by 82.8% to $1.8 million in 2025, then soared by 762.04% to $15.5 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's EBT are $15.5 million (Q2 2026), $4.2 million (Q1 2026), and $1.8 million (Q3 2025).